Home

Forum

    Biomaterials Translational Forum 2021-03: Biomaterials innovation for early treatment of osteoarthritis

  • 7 March 2021, Sunday

    13:30-16:00 (London); 8:30-10:00 (New York); 21:30-23:00 (Beijing)


    Zooming info:

    https://swanseauniversity.zoom.us/j/8266570519?pwd=aXdrN1pOUFhqSFlSYlFkQjVvNDRHQT09 


    Meeting ID: 826 657 0519

    Passcode: 718288

    Join by SIP: 8266570519@zoomcrc.com

    Join by H.323: 162.255.37.11 (US West)




    Forum Chair:

    Professor Chaozong Liu 

    Institute of Orthopaedic & Musculoskeletal Science, University College London, Royal National Orthopaedic Hospital, UK


    Introduction (5 minutes) : 

    Prof. Qian Wang 

    University of South Carolina, USA


    Biomaterials as artificial ECM in in vitro models (20 minutes)

    Prof. J. Miguel Oliveira 
    University of Minho; FIFA Medical Center, Portugal


    Cartilage Extracellular Matrix-derived Tissue Engineering Microtissues for Articular Cartilage Injury Repair (20 minutes)


    Prof. Jiang Peng 
    Orthopedic Institute of Chinese PLA General Hospital, PRC


    What are the lessons learn from the development of MACI?  (20 minutes)


    Prof. Minghao Zheng 
    The University of Western Australia, Australia


    Discussion + Q&A (30 minutes)

    Panelists *:

    Prof. Chaozong Liu

    Institute of Orthopaedic & Musculoskeletal Science, University College London, Royal National Orthopaedic Hospital, UK

     


    Prof.  Ilyas Khan

    Swansea University, UK

     

    Prof. Jiang Peng

    Orthopedic Institute of Chinese PLA General Hospital, PRC

     

    Prof. Minghao Zheng

    The University of Western Australia, Australia


    Introduction of Next Forum: Professor Jim Triffitt 11th April

     

    Organizing Committee *:

    Prof. Xu Cao

    Department of Orthopaedics, Johns Hopkins University, USA


    Prof. Xiaodong Guo

    Department of Orthopaedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, PRC


    Prof. Bin Li

    Institute of Orthopaedics, Soochow University, PRC


    Prof. Zengwu Shao

    Department of Orthopaedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, PRC


    Dr. Zhidao Xia

    Swansea University Medical School, Swansea, UK

                                                                                                                                                                         (* Arranged vertically in alphabetical order by their last name)    


    Brief CV of Prof. Chaozong Liu

    Chaozong Liu is a Professor of Biomedical Materials and the group leader of UCL Orthopaedic Bioengineering Research Group within the Division of Surgery & Interventional Science University College London, in associate with the Royal National Orthopaedic Hospital. 
    Chaozong’s research interests are directed toward the development of enhanced biomaterials for medical device applications with particular emphasis on the promoting interactions on the sub-micron to nanometre scale for applications in orthopaedic tissue engineering and regenerative medicine. His research in this area is supported by Innovate UK, Versus Arthritis UK, EU Horizon2020, EPSRC, Royal Society, etc. Core projects in this area include: Biomaterials innovation for early intervention of osteoarthritis; Novel osteochondral scaffold technology for treatment of large cartilage defects; Novel biomimetic articulating surface for enhancing bio tribological performance of total hip replacements; Titanium implant surface modification for reducing biofilm formation.  


    Brief CV of Prof. Ilyas Khan
    Dr Khan’s research group are working to make a concrete difference for people who suffer from diseases of the joints such as osteoarthritis. Their work ranges in scope from understanding the role of stem cells in the development and diseases of articular cartilage and other cartilaginous tissues found in the nose, ear and trachea, to tissue engineering of replacement cartilage for the repair and regeneration of cartilage defects. Many of these studies are carried out by a fine group of undergraduates, postgraduate Masters and PhD students and medical student researchers.
    Students joining the lab have opportunities to visit and work not only in the world class facilities in the Centre of Nanohealth, but also with our collaborators in the UK, Europe and worldwide.One of the most important aspects of work is to translate our world-leading advances and breakthroughs into the clinic and to do this we are actively working with our colleagues in the NHS to accelerate this process.


    Brief CV of Prof. Jiang Peng
    Jiang Peng is currently a professor and Director of Orthopedic Institute of Chinese PLA General Hospital (Beijing). Dr. Peng received his medical degree at Fourth Military Medical University, China (1995) and his PhD degree at Chinese PLA Medical School. His studies mainly focus on the peripheral nerve regeneration, bone and cartilage tissue engineering, and the treatment of the osteonecrosis of the femoral head with regenerative medicine. Dr. Peng has published about 155 peer review papers, such as in Science, Nat Medicine, Biomaterials. Dr. Peng received more than 10 grants including two 973 Projects and five NSFCs. He is Secretary general and standing committee member of Tissue Repair and Regeneration Branch of Chinese Medical Association Chinese Medical Association and Vice chairman of regenerative medicine branch of Chinese Anatomical Society. He is an editorial member for several scientific journals, including Journal of Orthopedic Translational Medicine, Orthopedic Journal of China, Chinese Journal of Joint Surgery (Electronic Edition), Chinese Medical Biotechnology.


    Brief CV of Prof. J. Miguel Oliveira
    Dr. J. Miguel Oliveira is a Principal Investigator that has focused his work on the field of biomaterials for tissue engineering, nanomedicine, stem cells and cell/drug delivery. He has been involved in the development of biomaterials from natural origin polymers (chitin, chitosan, carboxymethylchitosan, algae-based materials such as ulvan, silk-fibroin, and gellan gum and its derivatives) and bioceramics for a wide range of regenerative medicine applications including, bone, cartilage, osteochondral tissue, peripheral nerve, spinal cord injury, meniscus and intervertebral disc (IVD) regeneration. It is truly remarkable the range of processing routes proposed including 3D printing, in developing a whole range of structures spanning from micro/nanoparticles, micro/nanofibres, membranes, conduits or hydrogels. He is Vice-President of Institute 3Bs (I3Bs) at University of Minho. He is also Director of Pre-Clinical Research at the FIFA MEDICAL CENTER, PT. He has published more than 400 scientific contributions, 7 books, 6 special issues, and 106 book chapters, and 20 patents. He has participated in more than 300 communications and invited/keynote speaker in more than 50 plenary sessions. As February 2021, he has an h-index of 47 and received more than 8600 citations. He has been awarded several prizes, including Jean Leray Award 2015.

    Brief CV of Prof. Minghao Zheng

    Prof Minghao Zhang is currently Associate Dean of the Faculty of Health and Medical Science of the University of Western Australia. He graduated as Bachelor of Medicine at Shantou University in 1983, Master of Medicine at Sun Yet Sen University of Medical Science in 1987, PhD in 1993, Doctor of Medicine (MD) in 2000 at the University of Western Australia. He is fellow of the Royal College of Pathologists, UK,  the Royal College of Pathologists of Australasia and Royal Society of Medicine. He is the founder of regenerative medicine company Orthocell Ltd (ASX:OCC) in Australia. He is currently member of Faculty 1000 Prime and Associate Editor of Stem Cell Research and Therapy. His major research area is translational medicine and bioengineering of bone, cartilage and tendon. He developed a first cellular engineering product for cartilage repair MACI approved by FDA and Celgro collagen technology plateform for tendon, nerve, cartilage and bone regeneration. One of the collagen devices has already approved by FDA (510K), EU (CE mark) and TGA (ARTG) for guild bone regeneration. He has published over 200 papers and holds 30 patents.  He has over 8000 citation with H index of 51.

  • Pubdate: 2021-03-07    Viewed: 494